Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient

Journal of Immunological Methods

Volumn 418, Issue , 2015, Pages 61-65

  Freund, Natalia T ^a   Scheid, Johannes F ^a   Mouquet, Hugo ^b   Nussenzweig, Michel C ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b INSTITUT PASTEUR   (France)

Author keywords

Anti HIV 1 antibodies; Human Ig lambda; PCR; Single cell sorting; Somatic hypermutation

Indexed keywords

ANTIBODY; EPITOPE; IMMUNOGLOBULIN LAMBDA CHAIN; NEUTRALIZING ANTIBODY; SIGNAL PEPTIDE;

ARTICLE; GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION; FLOW CYTOMETRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MONONUCLEAR CELL; MUTAGENESIS; VIROLOGY;

FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN LAMBDA-CHAINS; LEUKOCYTES, MONONUCLEAR; MUTAGENESIS; MUTATION;

EID: 84930360491     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.01.011     Document Type: Article

References (26)

1. Berek, C., Milstein, C., Mutation drift and repertoire shift in the maturation of the immune response. Immunol. Rev., 96, 1987, 23.
2. Berek, C., Milstein, C., The dynamic nature of the antibody repertoire. Immunol. Rev., 105, 1988, 5.
3. Bournazos, S., et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell, 158(6), 2014, 1243.
4. Dey, B., et al. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog., 5(5), 2009, e1000445.
5. Halper-Stromberg, A., et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell, 158(5), 2014, 989.
6. Klein, F., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature, 492(7427), 2012, 118.
7. Klein, F., et al. Antibodies in HIV-1 vaccine development and therapy. Science, 341(6151), 2013, 1199.
8. Klein, F., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell, 153(1), 2013, 126.
9. Mouquet, H., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 467(7315), 2010, 591.
10. Mouquet, H., et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS ONE, 6(9), 2011, e24078.
11. Neuberger, M.S., Milstein, C., Somatic hypermutation. Curr. Opin. Immunol., 7(2), 1995, 248.
12. Pavri, R., Nussenzweig, M.C., AID targeting in antibody diversity. Adv. Immunol., 110, 2011, 1.
13. Pereyra, F., et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis., 200(6), 2009, 984.
14. Scheid, J.F., et al. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods, 343(2), 2009, 65.
15. Scheid, J.F., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature, 458(7238), 2009, 636.
16. Scheid, J.F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 333(6049), 2011, 1633.
17. Shingai, M., et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A, 2012, 19769.
18. Shingai, M., et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med., 211(10), 2014, 2061.
19. Tiller, T., et al. Autoreactivity in human IgG + memory B cells. Immunity, 26(2), 2007, 205.
20. Tiller, T., et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods, 329(1–2), 2008, 112.
21. Victora, G.D., Nussenzweig, M.C., Germinal centers. Annu. Rev. Immunol., 30, 2012, 429.
22. Wardemann, H., et al. Predominant autoantibody production by early human B cell precursors. Science, 301(5638), 2003, 1374.
23. Wei, X., et al. Antibody neutralization and escape by HIV-1. Nature, 422(6929), 2003, 307.
24. West, A.P. Jr., et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. U. S. A., 109(30), 2012, E2083.
25. West, A.P. Jr., et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl. Acad. Sci. U. S. A., 110(26), 2013, 10598.
26. West, A.P. Jr., et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell, 156(4), 2014, 633.